
Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target
Ultragenyx Pharmaceutical (RARE) Analyst Ratings
Bulls say
Ultragenyx Pharmaceutical Inc. is poised for growth, particularly with its lead product, Crysvita, generating over $1 billion in annual worldwide end-user revenue and expanding its market presence in Latin America and Turkey. The company's advancements in therapeutic developments, including UX111, have shown significant cognitive and functional improvements in patients compared to untreated ones, which could drive further commercial success. Additionally, the anticipated approval of UX111 is expected to contribute to achieving GAAP profitability by 2027, reinforcing the company's solid foundation and potential for value creation in the rare disease market.
Bears say
Ultragenyx Pharmaceutical Inc. faces a negatively skewed outlook due to several fundamental concerns impacting its financial stability. Key risks include lower-than-expected revenues from its core products, Crysvita and Dojolvi, alongside mounting competition, particularly from advancements in gene therapy that could challenge the efficacy of its drugs. Moreover, the company is vulnerable to clinical trial risks, regulatory hurdles, and uncertainties regarding commercial opportunities, all of which could significantly affect future sales estimates and operational funding.
This aggregate rating is based on analysts' research of Ultragenyx Pharmaceutical and is not a guaranteed prediction by Public.com or investment advice.
Ultragenyx Pharmaceutical (RARE) Analyst Forecast & Price Prediction
Start investing in Ultragenyx Pharmaceutical (RARE)
Order type
Buy in
Order amount
Est. shares
0 shares